Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation (NUC115132)

This study has been terminated.
(Slow progress in recruiting study patients)
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Sheng-Shun Yang, Taichung Veterans General Hospital
ClinicalTrials.gov Identifier:
NCT01627223
First received: June 18, 2012
Last updated: April 22, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2016
  Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)